Company announcements, clinical and scientific milestones, and media coverage.
[ NOV 9, 2026 / CORPORATE ]
Novastra reported further Phase 1 data for OAP-101 at SITC 2026, reinforcing feasibility and showing a consistent innate-to-Th1 pharmacodynamic signature across three patients.
Novastra Establishes Scientific Advisory Board and Appoints Senior Advisors
[NOV 5, 2026 / CORPORATE UPDATE]
Early Clinical Observations Reported by Investigators in the OAP-101 Investigator-Initiated Study
[NOVEMBER 2025 / CLINICAL MILESTONE]
First Patient Dosed in the OAP-101 Investigator-Initiated Study
[JANUARY 2025 / CLINICAL MILESTONE]
